{"schema_version":"secwatch.filing_event.v1","accession":"0000721371-25-000009","form_type":"8-K","ticker":"CAH","cik":"0000721371","company_name":"CARDINAL HEALTH INC","filed_at":"2025-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.182258+00:00","generated_at":"2026-05-27T06:03:36.517905+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cardinal Health Q2 non-GAAP EPS $1.93 (+2% YoY); guides FY25 $7.85-8.00, closes GI Alliance deal","bullets":["Revenue $55.3B (-4% YoY; +16% ex-large customer expiration); GAAP EPS $1.65, non-GAAP EPS $1.93.","Pharm & Specialty segment profit $531M (+7%); Global Medical Products profit $18M vs $11M.","FY2025 non-GAAP EPS guidance raised to $7.85-$8.00 from $7.75-$7.90; segment profit growth revised.","Completed acquisition of 73% of GI Alliance (gastroenterology MSO) and ION acquisition in Dec.","Started commercial-scale production of actinium-225 for theranostics; new distribution center underway."],"urls":{"canonical":"https://secwatch.observer/filing/0000721371-25-000009","json":"https://secwatch.observer/filing/0000721371-25-000009.json","markdown":"https://secwatch.observer/filing/0000721371-25-000009.md","text":"https://secwatch.observer/filing/0000721371-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/721371/000072137125000009/0000721371-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/721371/000072137125000009/cah-20250130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T06:03:36.517905+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}